← back to search

Stephen C. Textor

Mayo Clinic · US
Area of research
Pulmonary and Respiratory Medicine · Nephrology
Research interest
Research interests include Renal and Vascular Pathologies, Aortic aneurysm repair treatments, Chronic Kidney Disease and Diabetes, and Blood Pressure and Hypertension Studies.
h-index
79
citations
26,473
works
391
NIH funding
primary concept
email

Recent publications

Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic Nephropathy
Journal of the American Society of Nephrology 2021cited by 101position: middledoi
Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International 2021cited by 59position: middledoi
Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456
EBioMedicine 2020cited by 57position: middledoi
Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney
Scientific Reports 2018cited by 114position: middledoi
Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Endocrine Reviews 2017cited by 120position: lastdoi
Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number
American Journal of Hypertension 2017cited by 45position: middledoi
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD
American Journal of Kidney Diseases 2013cited by 196position: middledoi
Mesenchymal Stem Cells Improve Medullary Inflammation and Fibrosis after Revascularization of Swine Atherosclerotic Renal Artery Stenosis
PLoS ONE 2013cited by 105position: middledoi
Increased Circulating Inflammatory Endothelial Cells in Blacks With Essential Hypertension
Hypertension 2013cited by 28position: middledoi
A Mitochondrial Permeability Transition Pore Inhibitor Improves Renal Outcomes After Revascularization in Experimental Atherosclerotic Renal Artery Stenosis
Hypertension 2012cited by 121position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Lilach O. Lerman · Università Cattolica del Sacro Cuore6 papers (2012–2021)Amir Lerman · Mayo Clinic in Florida6 papers (2012–2021)John R. Woollard · Mayo Clinic4 papers (2012–2018)Alfonso Eirin · Mayo Clinic4 papers (2012–2017)Ahmed Saad · University of Alabama at Birmingham3 papers (2013–2018)David A. Calhoun · University of Alabama at Birmingham3 papers (2013–2017)Xiang-Yang Zhu · Mayo Clinic3 papers (2012–2013)Amrutesh S. Puranik · New York University2 papers (2018–2021)Luis A. Juncos · University of Alabama at Birmingham2 papers (2013–2017)Zilun Li · Sun Yat-sen University2 papers (2012–2013)Hui Tang · Anhui Agricultural University2 papers (2012–2017)Sandra M. Herrmann · Mayo Clinic2 papers (2012–2013)Monika L. Gloviczki · University of Alabama at Birmingham1 papers (2013–2013) · 1 papers (2018–2018)Jacques W.M. Lenders · Radboud University Nijmegen1 papers (2017–2017)James L. Kirkland · Maine Farmland Trust1 papers (2021–2021)Joseph T. Flynn · Seattle Children's Hospital1 papers (2013–2013) · 1 papers (2021–2021)George L. Bakris · University of Mississippi1 papers (2013–2013) · 1 papers (2013–2013)